Sodium Butyrate Inhibits Cell Growth and Stimulates p21 WAF1/CIP1 Protein in Human Colonic Adenocarcinoma Cells Independently of p53 Status

Nutrition and Cancer

Volumn 46, Issue 2, 2003, Pages 202-211

  Kobayashi, Hanako ^a   Tan, Er Mei ^a   Fleming, Sharon E ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BUTYRIC ACID; CYCLIN DEPENDENT KINASE INHIBITOR; CYCLIN DEPENDENT KINASE INHIBITOR 1; MESSENGER RNA; PROTEIN; PROTEIN P53; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CELL CYCLE G2 PHASE; CELL GROWTH; CELL STRAIN CACO 2; CELL STRAIN HT29; CELL STRAIN LOVO; CELL STRAIN LS513; CHROMATIN; CHROMATIN STRUCTURE; COLON; COLON ADENOCARCINOMA; CONTROLLED STUDY; FERMENTATION; GENE; GENE INDUCTION; GROWTH INHIBITION; HUMAN; HUMAN CELL; P21 GENE; PROMOTER REGION; PROTEIN SYNTHESIS; RNA STABILITY;

EID: 0345059371     PISSN: 01635581     EISSN: None     Source Type: Journal    
DOI: 10.1207/S15327914NC4602_14     Document Type: Article

References (51)

1. Fleming SE, Fitch MD, and Chansler MW: High-fiber diets: influence on characteristics of cecal digesta including short-chain fatty acid concentrations and pH. Am J Clin Nutr 50, 93-99, 1989.
2. Davido DJ, Richter F, Boxberger F, Stahl A, Menzel T, et al.: Butyrate and propionate downregulate ERK phosphorylation in HT-29 colon carcinoma cells prior to differentiation. Eur J Cancer Prev 10, 313-321, 2001.
3. Basson MD, Emenaker NJ, and Hong F: Differential modulation of human (Caco-2) colon cancer cell line phenotype by short chain fatty acids. Proc Soc Exp Biol Med 217, 476-483, 1998.
4. Gamet L, Daviaud D, Denis-Pouxviel C, Remesy C, and Murat JC: Effects of short-chain fatty acids on growth and differentiation of the human colon-cancer cell line HT29. Int J Cancer 52, 286-289, 1992.
5. Emenaker NJ and Basson MD: Short chain fatty acids differentially modulate cellular phenotype and c-myc protein levels in primary human nonmalignant and malignant colonocytes. Dig Dis Sci 46, 96-105, 2001.
6. Emenaker NJ, Calaf GM, Cox D, Basson MD, and Qureshi N: Short-chain fatty acids inhibit invasive human colon cancer by modulating uPA, TIMP-1, TIMP-2, mutant p53, Bcl-2, Bax, p21 and PCNA protein expression in an in vitro cell culture model. J Nutr 131, 3041S-3046S, 2001.
7. Fusunyan RD, Quinn JJ, Fujimoto M, MacDermott RP, and Sanderson IR: Butyrate switches the pattern of chemokine secretion by intestinal epithelial cells through histone acetylation. Mol Med 5, 631-640, 1999.
8. Barnard JA and Warwick G: Butyrate rapidly induces growth inhibition and differentiation in HT-29 cells. Cell Growth Differ 4, 495-501, 1993.
9. Whitehead RH, Young GP, and Bhathal PS: Effects of short chain fatty acids on a new human colon carcinoma cell line (LIM1215). Gut 27, 1457-1463, 1986.
10. Heerdt BG, Houston MA, and Augenlicht LH: Potentiation by specific short-chain fatty acids of differentiation and apoptosis in human colonic carcinoma cell lines. Cancer Res 54, 3288-3293, 1994.
11. Moss SF, Agarwal B, Arber N, Guan RJ, Krajewska M, et al.: Increased intestinal Bak expression results in apoptosis. Biochem Biophys Res Commun 223, 199-203, 1996.
12. Ruemmele FM, Dionne S, Qureshi I, Sarma DS, Levy E, et al.: Butyrate mediates Caco-2 cell apoptosis via up-regulation of pro-apoptotic BAK and inducing caspase-3 mediated cleavage of poly-(ADP-ribose) polymerase (PARP). Cell Death Differ 6, 729-735, 1999.
13. Velcich A, Palumbo L, Jarry A, Laboisse C, Racevskis J, et al.: Patterns of expression of lineage-specific markers during the in vitro-induced differentiation of HT29 colon carcinoma cells. Cell Growth Differ 6, 749-757, 1995.
14. Siavoshian S, Segain JP, Kornprobst M, Bonnet C, Cherbut C, et al.: Butyrate and trichostatin A effects on the proliferation/differentiation of human intestinal epithelial cells: induction of cyclin D3 and p21 expression. Gut 46, 507-514, 2000.
15. Litvak DA, Evers BM, Hwang KO, Hellmich MR, Ko TC, et al.: Butyrate-induced differentiation of Caco-2 cells is associated with apoptosis and early induction of p21Waf1/Cip1 and p27Kip1. Surgery 124, 161-169; discussion 169-170, 1998.
16. Avivi-Green C, Polak-Charcon S, Madar Z, and Schwartz B: Apoptosis cascade proteins are regulated in vivo by high intracolonic butyrate concentration: correlation with colon cancer inhibition. Oncol Res 12, 83-95, 2000.
17. Medina V, Afonso JJ, Alvarez-Arguelles H, Hernández C, and González F: Sodium butyrate inhibits carcinoma development in a 1,2-dimethylhydrazine-induced rat colon cancer. J Parenter Enteral Nutr 22, 14-17, 1998.
18. Mariadason JM, Corner GA, and Augenlicht LH: Genetic reprogramming in pathways of colonic cell maturation induced by short chain fatty acids: comparison with trichostatin A, sulindac, and curcumin and implications for chemoprevention of colon cancer. Cancer Res 60, 4561-4572, 2000.
19. Desilets A, Gheorghiu I, Yu SJ, Seidman EG, and Asselin C: Inhibition by deacetylase inhibitors of IL-1-dependent induction of haptoglobin involves CCAAT/enhancer-binding protein isoforms in intestinal epithelial cells. Biochem Biophys Res Commun 276, 673-679, 2000.
20. Nishimura A, Fujimoto M, Oguchi S, Fusunyan RD, MacDermott RP, et al.: Short-chain fatty acids regulate IGF-binding protein secretion by intestinal epithelial cells. Am J Physiol 275, E55-E63, 1998.
21. Basson MD and Hong F: Tyrosine kinase inhibitors reverse butyrate stimulation of human Caco-2 intestinal epithelial cell alkaline phosphatase but not butyrate promotion of dipeptidyl dipeptidase. Cell Biol Int 22, 339-344, 1998.
22. Qiao L, Koutsos M, Tsai LL, Kozoni V, Guzman J, et al.: Staurosporine inhibits the proliferation, alters the cell cycle distribution and induces apoptosis in HT-29 human colon adenocarcinoma cells. Cancer Lett 107, 83-89, 1996.
23. Espinos E, Le Van Thai A, Pomies C, and Weber MJ: Cooperation between phosphorylation and acetylation processes in transcriptional control. Mol Cell Biol 19, 3474-3484, 1999.
24. Espinos E and Weber MJ: Activation of the MAP kinase cascade by histone deacetylase inhibitors is required for the stimulation of choline acetyltransferase gene promoter. Brain Res Mol Brain Res 56, 118-124, 1998.
25. Kitzis A, Tichonicky L, Defer N, and Kruh J: Effect of sodium butyrate on chromatin structure. Biochem Biophys Res Commun 93, 833-841, 1980.
26. Smith PJ: n-Butyrate alters chromatin accessibility to DNA repair enzymes. Carcinogenesis 7, 423-429, 1986.
27. Yu JL, Rak JW, Coomber BL, Hicklin DJ, and Kerbel RS: Effect of p53 status on tumor response to antiangiogenic therapy. Science 295, 1526-1528, 2002.
28. Bunz F, Hwang PM, Torrance C, Waldman T, Zhang Y, et al.: Disruption of p53 in human cancer cells alters the responses to therapeutic agents. J Clin Invest 104, 263-269, 1999.
29. Palmer DG, Paraskeva C, and Williams AC: Modulation of p53 expression in cultured colonic adenoma cell lines by the naturally occurring lumenal factors butyrate and deoxycholate. Int J Cancer 73, 702-706, 1997.
30. Mahyar-Roemer M and Roemer K: p21 Waf1/Cip1 can protect human colon carcinoma cells against p53-dependent and p53-independent apoptosis induced by natural chemopreventive and therapeutic agents. Oncogene 20, 3387-3398, 2001.
31. Archer SY, Meng S, Shei A, and Hodin RA: p21 (WAF1) is required for butyrate-mediated growth inhibition of human colon cancer cells. Proc Natl Acad Sci USA 95, 6791-6796, 1998.
32. Enver T, Brewer AC, and Patient RK: Simian virus 40-mediated cis induction of the Xenopus beta-globin DNase I hypersensitive site. Nature 318, 680-683, 1985.
33. Ortiz BD, Cado D, Chen V, Diaz PW, and Winoto A: Adjacent DNA elements dominantly restrict the ubiquitous activity of a novel chromatin-opening region to specific tissues. EMBO J 16, 5037-5045, 1997.
34. Wu JT, Archer SY, Hinnebusch B, Meng S, and Hodin RA: Transient vs. prolonged histone hyperacetylation: effects on colon cancer cell growth, differentiation, and apoptosis. Am J Physiol Gastrointest Liver Physiol 280, G482-G490, 2001.
35. Kovarikova M, Pachemik J, Hofmanova J, Zadak Z, and Kozubik A: TNF-alpha modulates the differentiation induced by butyrate in the HT-29 human colon adenocarcinoma cell line. Eur J Cancer 36, 1844-1852, 2000.
36. Iacomino G, Tecce MF, Grimaldi C, Tosto M, and Russo GL: Transcriptional response of a human colon adenocarcinoma cell line to sodium butyrate. Biochem Biophys Res Commun 285, 1280-1289, 2001.
37. Coradini D, Pellizzaro C, Marimpietri D, Abolafio G, and Daidone MG: Sodium butyrate modulates cell cycle-related proteins in HT29 human colonic adenocarcinoma cells. Cell Prolif 33, 139-146, 2000.
38. Mariadason JM, Velcich A, Wilson AJ, Augenlicht LH, and Gibson PR: Resistance to butyrate-induced cell differentiation and apoptosis during spontaneous Caco-2 cell differentiation. Gastroenterology 120, 889-899, 2001.
39. Basson MD, Turowski GA, Rashid Z, Hong F, and Madri JA: Regulation of human colonic cell line proliferation and phenotype by sodium butyrate. Dig Dis Sci 41, 1989-1993, 1996.
40. Harrison LE, Wang QM, and Studzinski GP: Butyrate-induced G2/M block in Caco-2 colon cancer cells is associated with decreased p34cdc2 activity. Proc Soc Exp Biol Med 222, 150-156, 1999.
41. Tan S, Seow TK, Liang RC, Koh S, Lee CP, et al.: Proteome analysis of butyrate-treated human colon cancer cells (HT-29). Int J Cancer 98, 523-531, 2002.
42. Dulic V, Stein GH, Far DF, and Reed SI: Nuclear accumulation of p21Cip1 at the onset of mitosis: a role at the G2/M-phase transition. Mol Cell Biol 18, 546-557, 1998.
43. Winters ZE, Ongkeko WM, Harris AL, and Norbury CJ: p53 regulates Cdc2 independently of inhibitory phosphorylation to reinforce radiation-induced G2 arrest in human cells. Oncogene 17, 673-684, 1998.
44. Leschelle X, Delpal S, Goubern M, Blottiere HM, and Blachier F: Butyrate metabolism upstream and downstream acetyl-CoA synthesis and growth control of human colon carcinoma cells. Eur J Biochem 267, 6435-6442, 2000.
45. Chai F, Evdokiou A, Young GP, and Zalewski PD: Involvement of p21(Waf1/Cip1) and its cleavage by DEVD-caspase during apoptosis of colorectal cancer cells induced by butyrate. Carcinogenesis 21, 7-14, 2000.
46. Nakano K, Mizuno T, Sowa Y, Orita T, Yoshino T, et al.: Butyrate activates the WAF1/Cip1 gene promoter through Sp1 sites in a p53-negative human colon cancer cell line. J Biol Chem 272, 22199-22206, 1997.
47. Archer S, Meng S, Wu J, Johnson J, Tang R, et al.: Butyrate inhibits colon carcinoma cell growth through two distinct pathways. Surgery 124, 248-253, 1998.
48. Gartel AL, Goufman E, Najmabadi F, and Tyner AL: Sp1 and Sp3 activate p21 (WAF1/CIP1) gene transcription in the Caco-2 colon adenocarcinoma cell line. Oncogene 19, 5182-5188, 2000.
49. McBain JA, Eastman A, Nobel CS, and Mueller GC: Apoptotic death in adenocarcinoma cell lines induced by butyrate and other histone deacetylase inhibitors. Biochem Pharmacol 53, 1357-1368, 1997.
50. Strahl BD and Allis CD: The language of covalent histone modifications. Nature 403, 41-45, 2000.
51. Sowa Y, Orita T, Minamikawa-Hiranabe S, Mizuno T, Nomura H, et al.: Sp3, but not Sp1, mediates the transcriptional activation of the p21/WAF1/Cip1 gene promoter by histone deacetylase inhibitor. Cancer Res 59, 4266-4270, 1999.